Powering affordable care to the hearts of Missouri
Build healthier hearts in Missouri with new testing to help patients get ahead of diabetes, heart disease, and kidney disease.
Delivering information to transform health in Missouri
Heart disease is the leading cause of death in Missouri. Now, Quest is bringing you tests that will show patients if they are actively developing disease. Having this information gives you the opportunity for stage-targeted intervention and improved clinical outcomes. And that means better heart health throughout the state!
Insulin Resistance
Measure insulin resistance up to 10 years before a type 2 diabetes diagnosis—even in patients with normal glucose and hba1c—and give them time to change course.
Inflammation
Get a clearer picture of cardiovascular disease in your patients by measuring inflammation, the hidden risk factor, and fine tune therapy for the patients most at risk.
Kidney Profile
Detect kidney disease at its earliest stage in time to slowor even halt progression by combining kidney function (eGFR) and kidney damage (uACR) testing.
Powering Affordable Care
Quest’s advanced metabolic tests are priced comparable to traditional testing, and Quest costs are covered by Medicare and Medicaid and in-network with 99% of Missouri’s major health plans.
Helping you to improve health measures in Missouri
Quest Diagnostics has the data and resources you need to help your patients stay healthier. We are here to help you understand which patients to test, how to interpret the results and then provide support programs to help your patients make changes to improve their health and the community’s health scores. Learn more about Quest’s free 4myheart, a personalized care program to help improve heart health.
Reversing course on diabetes
Insulin resistance (IR) is an early warning sign of type 2 diabetes, occurring as much as 10 years prior to diagnosis. Quest’s Cardio IQ® Insulin Resistance Panel with Score is the first test available to detect and quantify insulin resistance in patients, even those with normal glucose or HbA1c. And because IR is a reversible disease state, lifestyle or pharmacological interventions can delay — and even prevent the onset of type 2 diabetes.
Consider IR testing in your patients with normal glucose and HbA1c who may be at risk of developing type 2 diabetes, and patients with clinical features associated with IR and prediabetes:
- Overweight or obese, particularly with central obesity
- Family history of diabetes or personal history of gestational diabetes mellitus
- Hypertension
- Acanthosis nigricans
- Polycystic ovary syndrome (PCOS)
Revealing the hidden risk for cardiovascular disease
Inflammation is a hidden risk of heart attacks and strokes and may help reveal why half of all heart attacks and strokes occur in patients with normal cholesterol levels. Quest’s Cardio IQ® Advanced Inflammatory Marker Testing uses a combination of blood and urine biomarkers to measure the level of inflammation within the artery wall, which is a key contributor to residual risk for heart attack and stroke.
Test results provide actionable information to individualize treatment options, including initiating or intensifying statin therapy, considering adjunct therapy, and setting diet and exercise targets with your patients.
Testing is recommended for patients with traditional cardiovascular risk factors. Consideration also should be given to testing in patients with:
- 5% Estimated ASCVD Risk
- Established cardiovascular disease, hypertension, or dyslipidemia
- Diabetes
- Metabolic syndrome
Detecting kidney disease earlier
Chronic kidney disease doesn’t happen overnight, yet 1 in 4 patients crash into dialysis with no advance warning. Traditional serum creatinine testing may only reveal half the CKD story. Guidelines now recommend combining kidney function (eGFR) and kidney damage (uACR) testing to detect kidney disease at its earliest stages—well in time to slow or even halt its progression with lifestyle changes or medicines.
Quest’s kidney profiles tests for both measures to help you diagnose CKD, manage disease progression, establish follow-up testing frequency, and know when to refer to a specialist. CKD testing is recommended annually for asymptomatic individuals at high risk for CKD, including patients with diabetes, hypertension, a family history of kidney disease, and cardiovascular disease.
Increasing access to advanced testing
Quest Diagnostics is committed to ensuring broad and affordable access to our testing services. See how we’re helping ensure you have the diagnostic insights you need at prices your patients can afford.
These tests are critical to understand risk of cardiometabolic disease, and we are working hard to make them affordable to most patients.
In-network with 99% of major health plans in Missouri:
Patient benefits are maximized by using an in-network provider, which helps to reduce out-of-pocket expenses through lower negotiated rates and all or partial payment by health plans for covered services.
See our list of
Medicare and Medicaid approve
Reduced list prices: We offer low patient list prices for many of our novel test service
Helpful patient assistance programs: Financial assistance or payment plans may be available to patients based on individual circumstance
